<li>blessed thistle<p>blessed thistle decreases effects of pantoprazole by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>clobazam<p>pantoprazole will increase the level or effect of clobazam by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown. Dosage adjustment may be required; CYP2C19 inhibitors may result in increased exposure to N-desmethylclobazam (active metabolite).</p></li><li>cyanocobalamin<p>pantoprazole decreases levels of cyanocobalamin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>darifenacin<p>darifenacin decreases effects of pantoprazole by Other (see comment). Minor/Significance Unknown. 
Comment: Effectiveness of proton pump inhibitors may be decreased  theoretically if administered with other antisecretory agents .</p></li><li>devil's claw<p>devil's claw decreases effects of pantoprazole by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>dexamethasone<p>dexamethasone will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>efavirenz<p>efavirenz will increase the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df, pantoprazole. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Based on drug interaction studies conducted with the components of Stribild, no clinically significant drug interactions have been either observed or are expected when coadministered with PPIs.</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate will increase the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown. Monitor for GI symptoms; net increased or decreased effect on PPI action unclear due to opposing CYP450 actions.<span><br><br></span>eslicarbazepine acetate decreases effects of pantoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Monitor for GI symptoms; net increased or decreased effect on PPI action unclear due to opposing CYP450 actions.</p></li><li>etravirine<p>etravirine will decrease the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>ferric carboxymaltose<p>pantoprazole will decrease the level or effect of ferric carboxymaltose by  increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>ketoconazole will increase the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>levothyroxine<p>pantoprazole decreases levels of levothyroxine by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>liothyronine<p>pantoprazole decreases levels of liothyronine by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>liotrix<p>pantoprazole decreases levels of liotrix by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>lisdexamfetamine<p>pantoprazole, lisdexamfetamine. Other (see comment). Minor/Significance Unknown. 
Comment: Reduced gastric acidity caused by proton pump inhibitors decreases time to Tmax for amphetamine and dextroamphetamine. AUC was unaffected. .</p></li><li>methamphetamine<p>pantoprazole decreases levels of methamphetamine by Other (see comment). Minor/Significance Unknown. 
Comment: Time to maximum concentration (Tmax) of amphetamine is decreased compared to when administered alone; monitor patients for changes in clinical effect and adjust therapy based on clinical response.</p></li><li>modafinil<p>modafinil will increase the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown. Net effect on pantoprazole actions unknown due to opposing effects of CYP450 enzymes; monitor<span><br><br></span>modafinil will increase the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Net effect on pantoprazole actions unknown due to opposing effects of CYP450 enzymes; monitor</p></li><li>oxcarbazepine<p>oxcarbazepine will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Unclear on net effect of pantoprazole action due to opposing effects by CYP450 enzymes; monitor<span><br><br></span>oxcarbazepine will increase the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown. Unclear on net effect of pantoprazole action due to opposing effects by CYP450 enzymes; monitor</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>phytoestrogens<p>pantoprazole decreases levels of phytoestrogens by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>thyroid desiccated<p>pantoprazole decreases levels of thyroid desiccated by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li>